Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Specialty Chemicals

Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates in two segments, Chemicals and Hotel. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, acetonitrile, dimethylcarbonate, propylene glycol, and propylene carbonate. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, choline chloride, mono-ethyl amine hydrochloride, and benzyl tri ethyl ammonium chloride; and pharma excipients, such as poly vinyl pyrrolidone. In addition, it operates Balaji Sarovar Premiere, a hotel in Solapur, Maharashtra, as well as engages in the provision of hotel, restaurant, and hospitality services. The company serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, pesticides and insecticides, water treatment chemical, optical brighteners, corrosion inhabitations, cosmetics, explosives, and foundry chemicals industries. It also exports its products to the United States, the United Kingdom, Argentina, Latin America, Canada, Israel, Australia, Bangladesh, Germany, Italy, Egypt, South Africa, and internationally. Balaji Amines Limited was incorporated in 1988 and is headquartered in Solapur, India.

Revenue projections:

Revenue projections for BALAMINES
Revenue projections for BALAMINES

With BALAMINES's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 5.170000
forwardPE 17.559608
debtToEquity 1.530000
earningsGrowth -0.157000
revenueGrowth -0.018000
grossMargins 0.426290
operatingMargins 0.133700
trailingEps 45.050000
forwardEps 0.000000

With a current ratio 5.17, BALAMINES demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
BALAMINES's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
BALAMINES's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
BALAMINES's negative gross and operating margins point to financial difficulties, as the company is incurring losses at both the production and operational levels. This suggests a potential decline in profitability and raises concerns about its financial outlook.

Price projections:

Price projections for BALAMINES
Price projections for BALAMINES

Over time, BALAMINES's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Recommendation changes over time:

Recommendations trend for BALAMINES
Recommendations trend for BALAMINES


Analysts are favoring BALAMINES with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider BALAMINES as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.